Heart failure & cardiomyopathiesGuideline or statement
Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance
- Clinical guidance document
Scope
As issued by the authors
Updated strategies and best practices for the diagnosis and management of transthyretin amyloid cardiomyopathy, focused on choice of disease-modifying therapies, HF therapies and future directions
Original publication
Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance. J Am Coll Cardiol. Published 31 October 2025. doi:10.1016/j.jacc.2025.09.004
Summarised from the published abstract; every number is checked against it